P-selectin and platelet-derived microparticles associated with monocyte activation markers in patients with pulmonary embolism.

Department of Internal Medicine, Kansai Medical Kohri Hospital, Neyagawa, Osaka, Japan.
Clinical and Applied Thrombosis/Hemostasis (Impact Factor: 1.58). 11/2003; 9(4):309-16. DOI: 10.1177/107602960300900406
Source: PubMed

ABSTRACT Platelet activation markers (platelet-derived microparticles and P-selectin on activated platelets), chemokines (monocyte chemotactic peptide and regulated on activation normally T-cell expressed and secreted), and soluble markers (sP-selectin, sE-selectin, sVCAM-1, and sCD14) were measured and compared in patients with pulmonary embolism (PE). These substances are thought to participate in the pathogenesis of PE. Levels of all of the platelet activation markers, chemokines, and soluble markers were higher in the patients with PE than in normal controls. Levels of platelet activation markers were also significantly increased postoperatively after total knee arthroplasty. Anti-platelet therapy significantly inhibited the elevation of platelet activation markers after total knee arthroplasty. These findings suggest that antiplatelet therapy may be useful for PE-related interaction of platelets, leukocytes, and endothelial cells.

  • [Show abstract] [Hide abstract]
    ABSTRACT: A computational study of a neutral Ni atom and Ni(II) atoms coordinated with CO and BF ligands was undertaken using density functional theory. Neutral compounds with general formula Ni(CO)x(BF)4−x (x=0–4) were predicted to have tetrahedral geometries, and cationic Ni(CO)x(BF)4-x2+ square-planar geometries. Sequential replacement of the CO molecules in the well known tetrahedral Ni(CO)4 molecule yields a substantially more stable tetrahedral Ni(BF)4 molecule, and substitution of the CO ligands in the square-planar [Ni(CO)4]2+ cation yields a more stable [Ni(BF)4]2+ analogue. Stable complexes were also obtained by substitution of the OC ligands by FB in the [Ni(OC)4]2+ cation.
    Chemical Physics Letters 11/2011; 516(4):146-148. · 1.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Thrombosis remains one of the leading causes of mortality and morbidity in developed countries. Relevant markers of the primary thrombotic risk however remain of limited accessibility, and clinicians are left with markers of essentially etiological nature. Fortunately, new entities, testifying to cellular activation or damage within the vascular compartment, have been recently described and are in the validation process. Microparticles (MP) are plasma membrane fragments released by stimulated or apoptotic cells. In the vascular compartment, they constitute a disseminated storage pool of bioactive effectors involved in inflammation, thrombosis, vascular tone, angiogenesis. Their biological characteristics are predetermined by the cytosolic and membraneous components hijacked from the activated cells. Their procoagulant properties are based on, (i) the accessibility of phosphatidylserine, a procoagulant aminophospholipid exposed after stimulation and necessary for the assembly of the blood clotting enzyme complexes, and (ii) the possible presence of tissue factor, the major initiator of the coagulation cascade. The incidence of MP in haemostatic processes has been demonstrated in physiology and pathology. They are now considered true pathogenic markers of the thrombotic risk.
    Annales Pharmaceutiques Françaises 03/2007; 65(2):75–84.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There is evidence that inflammatory bowel diseases (IBD) combine both inflammation and coagulation in their pathogenesis and clinical manifestations. Although platelets (PLT) are well known for their role in hemostasis, there are a rising number of studies supporting their considerable role as inflammatory amplifiers in chronic inflammatory conditions. IBD are associated with several alterations of PLT, including number, shape, and function, and these abnormalities are mainly attributed to the highly activated state of circulating PLT in IBD patients. When PLT activate, they increase in size, release a great variety of bio-active inflammatory and procoagulant molecules/particles, and express a variety of inflammatory receptors. These inflammatory products may represent a part of the missing link between coagulation and inflammation, and can be considered as possible IBD pathogenesis instigators. In clinical practice, thrombocytosis is associated both with disease activity and iron deficiency anemia. Controlling inflammation and iron replacement in anemic patients usually leads to a normalization of PLT count. The aim of this review is to update the role of PLT in IBD and present recent data revealing the possible therapeutic implications of anti-PLT agents in future IBD remedies.
    World Journal of Gastroenterology 03/2014; 20(12):3180-3190. · 2.43 Impact Factor